The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2015-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.13m08946PMID 25939027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute treatment of schizophrenia: introduction to the Word Federation of Societies of Biological Psychiatry guidelines.

  2014cited by this paper
• Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

  2013cited by this paper
• Is there shared decision making when the provider makes a recommendation?

  2013cited by this paper
• Patient resistance as agency in treatment decisions.

  2011cited by this paper
• Barriers to, and Strategies for, Starting a Long Acting Injection Clinic in a Community Mental Health Center

  2011cited by this paper
• Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines

  2010cited by this paper
• Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

  2010cited by this paper
• "Practicing medicine": patient perceptions of physician communication and the process of prescription.

  2010cited by this paper
• Barriers to insulin initiation and intensification and how to overcome them

  2009cited by this paper
• A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.

  2008cited by this paper
• Patients’ and Psychiatrists’ Perceptions of Clinical Decisions During Schizophrenia Treatment

  2008cited by this paper
• Shared decision making and long-term outcome in schizophrenia treatment.

  2007cited by this paper
• Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension.

  2006cited by this paper
• Patterns of communication through interpreters

  2006cited by this paper
• Attitudes of psychiatrists toward antipsychotic depot medication.

  2006cited by this paper
• Patterns of communication through interpreters: a detailed sociolinguistic analysis.

  2006cited by this paper
• Antipsychotic depot medication and attitudes of community psychiatric nurses.

  2005cited by this paper
• The Discourse of Medical Encounters

  2005cited by this paper
• Do patients with schizophrenia wish to be involved in decisions about their medical treatment?

  2005cited by this paper
• Practice guideline for the treatment of patients with schizophrenia, second edition.

  2004cited by this paper
• Symptoms and signs in particular: the influence of the medical concern on the shape of physician-patient talk.

  2004cited by this paper
• Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

  2003cited by this paper
• The Role of Physicians’ Recommendations in Medical Treatment Decisions

  2002cited by this paper
• Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders.

  2002cited by this paper
• When is a shared decision not (quite) a shared decision? Negotiating preferences in a general practice encounter.

  1999cited by this paper
• On interactional sociolinguistic method

  1999cited by this paper
• Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

  1998cited by this paper
• The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome.

  1990cited by this paper
• On the elicitation of preferences for alternative therapies.

  1982cited by this paper

• Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review

  2025cites this paper
• Understanding long-acting injectables in the context of treatment planning for schizophrenia: crafting a strategy

  2025cites this paper
• Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices

  2025cites this paper
• Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough

  2025cites this paper
• Antipsychotic prescription pattern in ASEAN: Comparison of antipsychotic prescription formulation and type from REAP-AP4 consortium study

  2025cites this paper
• Antipsychotic prescription patterns among schizophrenia patients in Guangdong Province, China’s 686 program: A retrospective study

  2024cites this paper
• Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus

  2024cites this paper
• A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

  2024cites this paper
• The place of long-acting injectable antipsychotics in the treatment of schizophrenia

  2023cites this paper
• Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting

  2023cites this paper
• Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data

  2023cites this paper
• Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches

  2023cites this paper
• Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges

  2023cites this paper
• Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review

  2023cites this paper
• Development and Evaluation of a Web-Based Educational Toolkit on the Knowledge, Attitudes, and Practices of Psychiatric Prescribers Regarding Long-Acting Injectable Antipsychotics

  2022influential citation
• Education to Improve Long-Acting Injectable Antipsychotic Use Education to Improve Long-Acting Injectable Antipsychotic Use

  2022cites this paper
• Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study.

  2022cites this paper
• Strategies for promoting treatment adherence in schizophrenia

  2022cites this paper
• Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study

  2022cites this paper
• How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia.

  2022cites this paper
• Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians

  2022cites this paper
• Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real‐world study in South Korea

  2021cites this paper
• Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions

  2021cites this paper
• Long-acting injectable antipsychotics: what, when, and how

  2021cites this paper
• A Program to Increase the Appropriate Use of Long-Acting Injectable Antipsychotic Medications in Community Settings.

  2021cites this paper
• Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

  2021cites this paper
• Une approche de la psychopharmacologie des premiers épisodes psychotiques axée sur le rétablissement

  2021cites this paper
• How and when to use clozapine

  2020cites this paper
• Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals

  2020cites this paper
• Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

  2020cites this paper
• Drug‐naïve first‐episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China

  2020cites this paper
• An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: A part of the ACNAP project ‘injectable medicines among patients with cardiovascular conditions’

  2020cites this paper
• NDT_A_286654 3197..3208

  2020cites this paper
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.

  2019influential citation
• Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada.

  2019cites this paper
• Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics: An Online Survey Study From India.

  2019cites this paper
• Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders

  2019cites this paper
• Udržovací léčba schizofrenie dlouhodobě působícími injekčními antipsychotiky – práce s pacienty a rodinnými příslušníky

  2019cites this paper
• C.01.04 Improving patient acceptance of maintenance treatment with long-acting injectables

  2019cites this paper
• Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics.

  2019cites this paper
• Long-Acting Injectable Antipsychotics

  2019cites this paper
• The Long-Acting Injectable Antipsychotics in Clinical Practice

  2019cites this paper
• Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2

  2018cites this paper
• A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.

  2018cites this paper
• Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period

  2018cites this paper
• Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

  2018cites this paper
• Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies.

  2017cites this paper
• Dlouhodobě působící antipsychotika v praxi

  2017cites this paper
• Perceptions and knowledge of antipsychotics among mental health professionals and patients

  2017cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia : Evaluating the Evidence Part 1 : Efficacy and Safety of LAIs � � �

  2016cites this paper
• Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia

  2016cites this paper
• Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians.

  2016cites this paper
• Antipsychotika-Depotbehandlung im Wandel der Zeit

  2016cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

  2016cites this paper
• Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

  2016cites this paper
• Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

  2016cites this paper
• Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia

  2016cites this paper
• Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Approaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships.

  2016cites this paper
• The treatment of schizophrenia: Can we raise the standard of care?

  2016influential citation
• Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia

  2014cites this paper